Autor
La barrera hematoencefálica (BHE) es un dispositivo selectivo que hace de filtro entre la sangre circulante y los tejidos cerebrales y que impide la penetración de sustancias nocivas al cerebro. Sin embargo, algo que por un lado resulta beneficioso, ya que evita la entrada de sustancias perjudiciales, se convierte en un obstáculo para la eficacia de determinados fármacos que ejercen su efecto terapéutico en el cerebro.
La BHE fue el hilo conductor del undécimo simposio internacional organizado por la Fundación Dr. Antonio Esteve en octubre de 2004. A lo largo de tres jornadas, 19 investigadores de todo el mundo presentaron sus trabajos sobre este dispositivo con el objetivo de conocer algo más sobre él: las posibles alteraciones de esta barrera en condiciones patológicas, las modalidades de transporte y las nuevas posibilidades de desarrollo de nuevos fármacos y nuevos sistemas de transporte con el fin de favorecer el paso de los principios activos a través de la BHE. No es cosa menor si tenemos en cuenta que de ello depende en buena medida el desarrollo de medicamentos para el tratamiento de enfermedades tan importantes como el Alzheimer, el Parkinson o la Esclerosis Múltiple.
Albert de Boer, del departamento de Farmacología del Leiden-Amsterdam Center for Drug Research fue el encargado de moderar esta reunión científica y de editar este volumen número 11 de la serie Esteve Foundation Symposia, publicada por Elsevier Science.
| Capítulos | ||
| Introduction | Albertus G. de Boer | [wpdm id=311 type=”btn”] |
| List of participants | [wpdm id=312 type=”btn”] | |
| 1. Physiology of the blood-brain barrier and its consequences for drug transport to the brain | N. Joan Abbott | [wpdm id=289 type=”btn”] |
| 2. The blood-brain barrier and treatment of lysosomal storage diseases | J.M. Aerts / M.J. van Breemen / A.R. Bussink / J. Brinkman / C.E.M. Hollak / M. Langeveld / G.E. Linthors / A.C. Vedder / M. de Post | [wpdm id=290 type=”btn”] |
| 3. The priorities/needs of the pharmaceutical industry in drug delivery to the brain | Michel Lemaire / Sandrine Desrayaud | [wpdm id=291 type=”btn”] |
| 4. Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems | William M. Pardridge | [wpdm id=292 type=”btn”] |
| 5. Carrier-mediated transport to enhance drug delivery to brain | Quentin R. Smith | [wpdm id=293 type=”btn”] |
| 6. Influx transporters and drug targeting: Application of peptide and cation transporters | Akira Tsuji | [wpdm id=294 type=”btn”] |
| 7. Application of nanoparticles for the delivery of drugs to the brain | Jorg Kreuter | [wpdm id=295 type=”btn”] |
| 8. Application, efficiency and cargo-dependence of transport peptides | J.P.M. Langedijk / T. Olijhoek / R.H. Meloen | [wpdm id=296 type=”btn”] |
| 9. Efflux transport systems at the blood-brain barrier and blood CSF barrier | Hiroyuki Kusuhara / Yuichi Sugiyama | [wpdm id=297 type=”btn”] |
| 10. Experimental models to evaluate the role of P-glycoprotein in the blood-brain tumor barrier | Olaf van Tellingen / E. Marleen Kemper / Tessa Buckle | [wpdm id=298 type=”btn”] |
| 11. Overcoming MDR at the blood-brain barrier | G. Fricker | [wpdm id=299 type=”btn”] |
| 12. Reversal of MDRl/P-glycoprotein-mediated multidrug resistance by RNA interference | H. Lage | [wpdm id=300 type=”btn”] |
| 13. The multidrug resistance protein BMDP/ABCG2: A new and highly relevant efflux pump at the blood-brain barrier | A. Drees / E. Hollnack / T. Eisenblatter / H.J. Galla | [wpdm id=301 type=”btn”] |
| 14. Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood-brain barrier | R. Gabathuler / G. Arthur / M. Kennard / Q. Chen / S. Tsai / J. Yang / W. Schoorl / T.Z. Vitalis / W.A. Jefferies | [wpdm id=302 type=”btn”] |
| 15. Diphtheria toxin receptor-targeted brain drug delivery | P.J. Gaillard / A. Brink / A.G. de Boer | [wpdm id=303 type=”btn”] |
| 16. The use of Pep: Trans vectors for the delivery of drugs into the central nervous system | J.M. Scherrmann / J. Temsamani | [wpdm id=304 type=”btn”] |
| 17. Single domain antibodies as blood-brain barrier delivery vectors | A. Abulrob / J. Zhang / J. Tanha / R. MacKenzie / D. Stanimirovic | [wpdm id=305 type=”btn”] |
| 18. The blood-brain barrier in trauma, stroke and edema | J. Verlooy / J. Van Reempts | [wpdm id=306 type=”btn”] |
| 19. The blood-brain barrier in multiple sclerosis | S. McQuaid / J. Kirk | [wpdm id=307 type=”btn”] |
| 20. The blood-brain barrier in diabetes mellitus: A critical review of clinical and experimental findings | E. Tolia / I.P. Fouyas / P.A.T. Kelly / I.R. Whittle | [wpdm id=308 type=”btn”] |
| Final discussion | A.G. de Boer | [wpdm id=310 type=”btn”] |
| Novel opportunities for the treatment of brain diseases | A.G. de Boer | [wpdm id=309 type=”btn”] |
- Drug transport(ers) and the diseased brain Introduction
- Albertus G. de Boer
- Descargar
- Drug transport(ers) and the diseased brain List of participants
- Descargar
- 1. Physiology of the blood-brain barrier and its consequences for drug transport to the brain
- N. Joan Abbott
- Descargar
- 2. The blood-brain barrier and treatment of lysosomal storage diseases
- J.M. Aerts / M.J. van Breemen / A.R. Bussink / J. Brinkman / C.E.M. Hollak / M. Langeveld / G.E. Linthors / A.C. Vedder / M. de Post
- Descargar
- 3. The priorities/needs of the pharmaceutical industry in drug delivery to the brain
- Michel Lemaire / Sandrine Desrayaud
- Descargar
- 4. Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems
- William M. Pardridge
- Descargar
- 5. Carrier-mediated transport to enhance drug delivery to brain
- Quentin R. Smith
- Descargar
- 6. Influx transporters and drug targeting: Application of peptide and cation transporters
- Akira Tsuji
- Descargar
- 7. Application of nanoparticles for the delivery of drugs to the brain
- Jorg Kreuter
- Descargar
- 8. Application, efficiency and cargo-dependence of transport peptides
- J.P.M. Langedijk / T. Olijhoek / R.H. Meloen
- Descargar
- 9. Efflux transport systems at the blood-brain barrier and blood CSF barrier
- Hiroyuki Kusuhara / Yuichi Sugiyama
- Descargar
- 10. Experimental models to evaluate the role of P-glycoprotein in the blood-brain tumor barrier
- Olaf van Tellingen / E. Marleen Kemper / Tessa Buckle
- Descargar
- 11. Overcoming MDR at the blood-brain barrier
- G. Fricker
- Descargar
- 12. Reversal of MDRl/P-glycoprotein-mediated multidrug resistance by RNA interference
- H. Lage
- Descargar
- 13. The multidrug resistance protein BMDP/ABCG2: A new and highly relevant efflux pump at the blood-brain barrier
- A. Drees / E. Hollnack / T. Eisenblatter / H.J. Galla
- Descargar
- 14. Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood-brain barrier
- R. Gabathuler / G. Arthur / M. Kennard / Q. Chen / S. Tsai / J. Yang / W. Schoorl / T.Z. Vitalis / W.A. Jefferies
- Descargar
- 15. Diphtheria toxin receptor-targeted brain drug delivery
- P.J. Gaillard / A. Brink / A.G. de Boer
- Descargar
- 16. The use of Pep: Trans vectors for the delivery of drugs into the central nervous system
- J.M. Scherrmann / J. Temsamani
- Descargar
- 17. Single domain antibodies as blood-brain barrier delivery vectors
- A. Abulrob / J. Zhang / J. Tanha / R. MacKenzie / D. Stanimirovic
- Descargar
- 18. The blood-brain barrier in trauma, stroke and edema
- J. Verlooy / J. Van Reempts
- Descargar
- 19. The blood-brain barrier in multiple sclerosis
- S. McQuaid / J. Kirk
- Descargar
- 20. The blood-brain barrier in diabetes mellitus: A critical review of clinical and experimental findings
- E. Tolia / I.P. Fouyas / P.A.T. Kelly / I.R. Whittle
- Descargar
- Final discussion
- A.G. de Boer
- Descargar
- Novel opportunities for the treatment of brain diseases
- A.G. de Boer
- Descargar
